Thinking Bigger About Regenerative Medicine

Over the past 2 decades, medical aesthetics has been defined by 3 major injectable categories:

1. Neuromodulators changed how we approach dynamic facial lines.

2. Hyaluronic acid fillers provided a versatile, generally low-inflammatory, and reversible approach to restoring volume.^1,2

3. Biostimulators introduced a biological dimension by harnessing a well-established foreign body response to promote collagen deposition.^3-5

Each of these has advanced the field. Yet despite advances in formulation, rheology, duration of effect, injection techniques, and combination therapy, aesthetics has seen relatively few fundamentally new injectable mechanisms since hyaluronic acid fillers and particulate biostimulators became established.^1,6

Today, the word “regeneration” has become increasingly prominent—appearing in scientific programs, congress presentations, peer-reviewed publications, product marketing, and medical education—reflecting an important shift in what patients and clinicians desire: outcomes that look natural, integrate with the tissue, and address more than temporary correction. Broader use of the term, however, has not necessarily produced greater clarity about how regeneration is defined.^1-3,6

REGENERATION REQUIRES MORE 
THAN COLLAGEN

Recent reviews and expert consensus efforts have helped organize regenerative aesthetics around 3 familiar pillars: cells, biochemical cues, and scaffolds.^6,7 These frameworks are valuable because they move the discussion beyond simple volume replacement. They also expose an important evidentiary gap.^2,6

Recent studies have shown that poly-L-lactic acid influences gene pathways associated with extracellular matrix (ECM) remodeling and tissue repair.⁴ These findings are important, but changes in gene expression alone do not demonstrate tissue regeneration.⁸ Regeneration ultimately requires evidence of organized tissue formation, vascular integration, and restoration of native tissue.^2,7

There is direct protein-level and histologic evidence for both calcium hydroxylapatite and poly-L-lactic acid, particularly for collagen deposition and localized ECM remodeling.^3-5 However, increases in collagen, elastin, or selected matrix proteins, although biologically meaningful, do not by themselves demonstrate reconstruction of an organized, living, and tissue-appropriate compartment.^2,3

A PRACTICAL BIOLOGICAL STANDARD

In tissue engineering and regenerative medicine, 3 interacting elements form the foundation of regeneration:^6,7

1. Cells, which are capable of populating, maintaining, and remodeling tissue.

2. Biochemical signals, which regulate cell migration, proliferation, differentiation, and matrix production.

3. An ECM or scaffold, which provides structural support and biochemical and mechanical cues that organize tissue formation.

These elements do not function independently. Cells respond to soluble signals, but they also read the architecture, stiffness, composition, and organization of the matrix around them. The ECM is therefore not merely a container: it is an integral component of the local tissue microenvironment.^2,7

From this perspective, pathway activation and collagen production could be viewed as components of regeneration, but not necessarily as proof that regeneration has occurred.² A scientifically meaningful regenerative claim should progress through an evidence hierarchy: gene expression, protein production, organized tissue formation, and, ultimately, functional tissue restoration.^2,7

WHAT EXISTING CATEGORIES CONTRIBUTE

Hyaluronic acid fillers remain foundational to aesthetic medicine. They provide predictable volume, generally produce limited inflammation, are resorbed gradually, and can be enzymatically reversed.^1,2 These attributes have contributed significantly to their safety, versatility, and broad physician and aesthetic provider acceptance.¹

Biostimulators represent a meaningful next step. Materials such as calcium hydroxylapatite and poly-L-lactic acid have moved the field beyond volume replacement by promoting host–cell activity and extracellular matrix deposition.^3-5 Their increasing use reflects growing interest in tissue quality and biological remodeling over time.^3-6

Particulate biostimulators rely, to varying degrees, on a controlled host response, they are not readily reversible, and they may remain in tissue for extended periods beyond cosmetic correction.^2,4,5 Their most established biological effect is matrix stimulation—particularly, collagen deposition.^2-5

The next opportunity is to build upon what each of these foundational categories has taught us. The next step may be a regenerative injectable that may combine injectability, immediate structural support, low inflammation, and gradual resorption with an ECM environment capable of supporting cellular ingrowth, vascular interaction, and organized, tissue-appropriate remodeling.^2,6,7

A MORE PRECISE DEFINITION OF BIOREGENERATION

Bioregeneration is the restoration of living tissue through the coordinated interaction of resident cells, biological signals, and a temporary ECM scaffold that supports organized tissue ingrowth and remodeling.^2,7

This sets a higher evidentiary bar than showing increased expression of genes or deposition of collagen alone.² To support a bioregenerative claim, the evidence should show that cells migrate into the material, blood vessels grow into it, the scaffold remodels and resorbs over time, and the tissue that remains reflects the structure and function of the native tissue.^2,7

THE NEXT CATEGORY

The next major category in injectable aesthetics may therefore be neither another filler nor another collagen stimulator. Instead, it may involve temporary, biologically responsive scaffolds providing structural support while creating an environment in which the body’s own cells and signals can participate in organized tissue formation.^2,6,7

The market appears ready for it. Patient expectations are shifting toward natural tissue integration, improved tissue quality, and durability.^3,6 Glucagon-like peptide-1 receptor agonist–associated weight loss is also exposing facial and body soft-tissue changes that extend beyond localized volume correction or correction of an isolated line or fold.⁸ At the same time, the term “regeneration” is being adopted faster than the evidence standards needed to define it.^2,3

The opportunity now is to define regeneration scientifically before the word loses its meaning commercially. A true regenerative category should be built by establishing clear biological criteria, generating evidence across the full hierarchy from molecular signaling to organized tissue, and developing materials intentionally designed around the fundamental requirements of tissue regeneration.^2,7 That is the inflection point now facing aesthetic medicine, and where the field’s next meaningful innovation is likely to emerge.